# Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors

> **NCT07490236** · PHASE1 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Trilaciclib
- CDK4/6-dependent Solid Tumors

## Interventions

- **DRUG:** Trilaciclib group

## Key facts

- **NCT ID:** NCT07490236
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490236, "Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07490236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*